Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders

A method of treating neuroinflammatory disease in a subject in need thereof comprising, administering to said subject an effective amount of an IL-17A binding antibody or antigen-binding portion thereof, wherein said IL-17A binding antibody or antigen-binding portion thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL);

• a. wherein said VH comprises the three Complementarity Determining Regions (CDRs) of the amino acid sequence set forth as SEQ ID NO:
• 12 and wherein said VL comprises the three CDRs of the amino acid sequence set forth as SEQ ID NO:43;
• b. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:42, SEQ ID NO:23, SEQ ID NO:
• 11;
• or
• c. c. wherein said VH comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and wherein said VL comprises, in sequence, the three CDRs set forth as amino acid sequences SEQ ID NO:41, SEQ ID NO:5, SEQ ID NO:6, and wherein said antibody inhibits proinflammatory cytokine release from astrocytes.